We Can Make Medical Breakthroughs
Groundbreaking medical advances are the result of new ideas and approaches developed through clinical research. Our Cancer Center and Cardiovascular Center participate in clinical research
and trials. For more information, call 818-885-5391.
Research allows us to find better methods to prevent, diagnose and treat cancer and discovering the treatments of tomorrow is something we all strive for.
Northridge Hospital is currently offering 85 clinical research opportunities in the areas of Cardiology, Diabetes, Endocrinology, Gynecology, Ophthalmology, Emergency Medicine, Neurology, Stroke, Pain Management, Rheumatology, Immunology Radiation Oncology and Cancer.
Clinical trial participants may be among the first to receive new research treatments before they are widely available. You can ask your physician if you may be a candidate for one of the trials.
The Leavey Cancer Center is participating in 15 promising trials in the areas of prevention and treatment for brain cancer, breast cancer, gastrointestinal and rectal cancer, genitourinary, lung cancer, lymphoma, metastatic cancer, neuropathy and prostate cancer. Our trials are with National Cancer Institute designated cooperative groups and in conjunction with UCLA.
Consider the breast cancer trial in which participants took Letrozole—a cancer-fighting drug. The trial concluded ahead of schedule when data indicated the drug significantly improved disease-free survival. We also participated in STAR (Study of Tamoxifen and Raloxifene), the largest trial ever conducted on breast cancer prevention.
For nearly 30 years, Northridge Hospital has partnered with some of the nation’s most respected institutions in the most innovative clinical research trials. You can find more information on clinical research by visiting ClinicalTrials.gov or CenterWatch.com which lists national and international clinical trials.
Current Open Trials
S0500 A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.
SWOG 0230 Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer.
S0715 Randomized Placebo-controlled Trial of Acetyl-L-Carnitine (ALC) For the Prevention of Taxane Induced Neuropathy, Phase III.
C90601 A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab (IND #7921, NSC #704865) to gemcitabine, cislpatin, and placebo in patients with Advanced transitional cell carcinoma.
SWOG 0424 Molecular Epidemiology Case Series Study of Non-small Cell Lung Cancer In Smoking and Non-smoking Women and Men.
E CTSU C50303 Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas Metastatic Cancer.
C70604 A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer.
CTSU C90203 Randomized phase III study of neo-adjuvant docetaxel and androgen deprivaton prior to radical prostatectomy versus immediate radical prostatectomy in patient with high rick, clinically localized prostate cancer.
RTOG 0534 A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy.
CALGB170601 A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN).